Experience with flash glucose monitoring: Impact on glycemic control and quality of life in type 1 diabetes within a public healthcare program
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Flash glucose monitoring (FGM) systems enhance diabetes management for type 1 diabetes patients. Users reported high satisfaction and perceived improvements in daily life, despite no significant changes in quality of life scores.
Area Of Science
- Endocrinology
- Diabetes Technology
- Patient-Reported Outcomes
Background
- Flash glucose monitoring (FGM) offers real-time glucose readings, presenting an alternative to traditional blood glucose monitoring.
- FGM has the potential to improve diabetes management and quality of life (QoL) for individuals with type 1 diabetes mellitus (T1DM).
Purpose Of The Study
- To evaluate patient satisfaction, user experience, glycemic control, and QoL in adults with T1DM using FGM in Brazil's public healthcare system.
- To compare FGM with self-monitoring of blood glucose (SMBG) regarding patient-reported outcomes.
Main Methods
- Prospective cohort study utilizing both qualitative and quantitative methods.
- 83 adults with T1DM newly enrolled in a public FGM program completed questionnaires at baseline and 3 months.
- Included the Brazilian version of the Diabetes Quality of Life Measure and glycemic control metrics.
Main Results
- After 3 months, mean time in range was 68.96%, mean glucose management indicator was 6.69%, and 60.9% had a coefficient of variation ≥36%.
- Participants reported higher satisfaction with FGM compared to SMBG, noting improvements in comfort, practicality, and diabetes management.
- QoL scores showed a slight improvement but were not statistically significant; however, perceived benefits in self-management were reported.
Conclusions
- FGM use is associated with high patient satisfaction and positive user experiences in a public healthcare setting.
- While not statistically significant, FGM use appears to offer perceived benefits for diabetes self-management and daily living.
- FGM demonstrates potential as a valuable tool for improving the daily lives of individuals with T1DM.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...